Immatics Announces $602 Million Business Combination with Arya Sciences Acquisition Corp., to Create a Publicly Listed Leader in TCR-based Immunotherapies

The Life Sciences and Special Purpose Acquisition Companies (SPACs) teams advised Immatics Biotechnologies GmbH on its definitive business combination agreement with Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a deal valued at approximately $602 million after new commitments from leading institutional investors for an additional $104 million in private placement in public equity (“PIPE”) and $148 million currently in Arya’s trust account.

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies. Arya is a special purpose acquisition company (“SPAC”), sponsored by Perceptive Advisors.

The Goodwin team led by Jocelyn Arel, Mitch Bloom and Michael Patrone and included Rob Intile and Kristen Kennedy (M&A), Edwin O’Connor, Patricia Mets and Humza Bokhari (Capital Markets), Sarah Bock and James Devendorf (Benefits), Theresa Kavanaugh and Megan Gustafson (Intellectual Property), Daniel Karelitz, Alex Apostolopoulos and Nicole Spiteri (Tax), Roger Cohen (Healthcare Regulatory), Stephanie Philbin and Steven Tjoe (FDA), Jennifer Fay, Deborah Birnbach and Alicia Rubio-Spring (Litigation), and Paul Jin and Kara Kuritz (Antitrust).

For more details, read the press release and article in PE Hub.